Excited to share our new paper, out today on Nature Genetics where we use 421 #WGS to reconstruct the evolutionary history of multiple myeloma #mmsm (🔥🔥). Great collaboration with Heidelberg Myeloma Sylvester Comprehensive Cancer Center Mayo Clinic Memorial Sloan Kettering Cancer Center MSK Department of Medicine ⁦.

Just published in nature, Clements et al. reveal that axonal injury is a key driver of early GBM progression, overturning the assumption that early GBM growth is purely tumor-cell intrinsic and showing neurons profoundly shape GBM biology throughout their life cyle

Very proud of these two! Kellie Wise (Kellie Wise) Anna Pascual-Reguant Dr. Jasmine Plummer 👩🏻‍🔬🧬🇨🇦🇺🇸 Holger Heyn CNAG St. Jude Research #STAMP Imaging-based multimodal profiling of single cells with STAMP | Nature Reviews Genetics nature.com/articles/s4157…

🚨 NEWS 🚨 Health Canada and PHAC grants market authorization for glofitamab + GemOx, for the treatment of adult patients with R/R DLBCL who are ineligible for auto-HSCT; based on results from the phase III STARGLO trial. Learn more: loom.ly/eKZax7A #lymphoma #lymsm #MedNews

ASCI Early-Career Award Nominations are open: Emerging-Generation + Young Physician-Scientist Awards High-level recognition on this critical career path! Awardees access JointMeeting, networking, and career-development opportunities. Deadline: Oct. 15 More at:

1/ Most biologists fail at computation not because it’s hard— but because they start in the wrong place. Here’s the roadmap I wish I had 12 years ago.

Agreed. America needs better access to and reimbursement for primary care. But our deficiencies in primary care aren’t the main drivers of disappointing life expectancy statistics.

Many researchers overlook or misinterpret statistical assumptions. Misunderstanding these assumptions can lead to using the wrong statistical tests, drawing inaccurate conclusions, and weakening a study’s credibility. Even common analyses can produce misleading results if their

I was looking for a good visualization of lifetime risk of disease for 'important' mutations, and really like this one on breast cancer. From nejm.org/doi/full/10.10…

You are not alone in wondering what are the implications of the FDA ODAC vote last year on MRD negativity (and CR) as a surrogate endpoint for clinical trials in myeloma. I try to piece it together in this approachable primer for ASCO daily news! Link below 👇

Ready to elevate your model-building skills? Elod Pal Csirmaz helps you solve a common data science problem by demonstrating how to derive a continuous score from categorical labels. towardsdatascience.com/estimating-fro…

Cracking the POD24 code in follicular lymphoma ow.ly/CFVs50WLFun #lymphoidneoplasia

One ‘explanation’ offered to justify the use of inferior control treatments in cancer RCTs is that they were conducted in low- and middle-income countries where superior treatments are not affordable. A new study tests this claim. Bishal Gyawali, MD, PhD, FASCO bmjoncology.bmj.com/content/4/1/e0…

Free course: Intro to Computational Biology by Mike Love, author of DESeq2. biodatascience.github.io/compbio/

If you're a faculty member, how much travel funding/professional development money do you get from your department or university to attend conferences each year? We're an R1 (as of this year) and only get $1000 which covers like half of one conference's expenses... :(

For more than 50 years, WashU has trained doctors who are also scientists. Thanks to Roy and Diana Vagelos, this program continues to prepare the next generation of leaders who turn discoveries into life-saving treatments. bit.ly/3IEdMrj

Flight 10 was the perfect finish for my latest artwork, a composite image I’ve been working on since I first started chasing rockets nearly 2 years ago. This celebration of human ingenuity is titled “The Road to Mars”. Get it in print at the link in my bio for a short time.

The new NIH grant review format and the iron law of unintended consequences drugmonkey.wordpress.com/2025/08/27/the… via Drug Monkey

Patient-reported outcome measures add value as clinical trial endpoints. nature.com/articles/s4159… nature Nature Portfolio Nature Medicine #CancerResearch #ClinicalTrials #PallOnc #SuppOnc

Despite its rising incidence 📈 and poor outcomes, we still have a limited understanding of the biology driving early-onset colorectal cancer (<50y). Most prior studies were small, inconsistent, or confounded by MSI and treatment exposure. In JCO OA, Futreal, Scott Kopetz , and